Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs

Cancer Gene Therapy

Volumn 14, Issue 11, 2007, Pages 875-884

  Folmer, Y ^a,b   Schneider, M ^a,c   Blum, H E ^a   Hafkemeyer, P ^a,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SLK Kliniken Heilbronn   (Germany)

^c Cellgenix GmbH   (Germany)

^d Kreiskrankenhaus Emmendingen   (Germany)

Author keywords

ABCC2; Adenovirus; Antisense; Drug resistance; Oligonucleotides

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; FLUO 3; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 2 ANTISENSE DNA; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GENE THERAPY; CANCER RESISTANCE; CELL CULTURE; CELL STRAIN HEPG2; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR REGRESSION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA, ANTISENSE; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TRANSDUCTION, GENETIC; VINCRISTINE;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 35048895704     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701082     Document Type: Article

References (27)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
3. Cui Y, König J, Buchholz U, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, ABCC2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-937.
4. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA et al. Analysis of expression of cMOAT (ABCC2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537-3547.
5. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M et al. (1997): A canalicular multispecific organic anion transporter (cMOAT) antisense DNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 5475-5479.
6. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-237.
7. Keppler D, Jedlitschky G, Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 1998; 292: 607-616.
8. Tsuruo T, Iida H, Ohkochi E, Tsukagoshi S, Sakurai Y. Establishment and properties of vincristine-resistant human myelogenous leukemia K562. Jpn J Cancer Res 1983; 74: 751-758.
9. Teboekhorst PAW, Vankapel J, Schoester M, Sonneveld P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analog SDZ-PSC-833 in chinese hamster ovary cells expressing the mdr1-phenotype. Cancer Chemother Pharmacol 1992; 30: 238-242.
10. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
11. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987; 47: 5875-5879.
12. Brown T, Mackey K. Analysis of RNA by Northern and slot blot hybridization. In: Chanda VB (ed). Current Protocols of Molecular Biology. John Wiley&Sons: New York, 1997 pp 4.9.1-4.9.14.
13. Ihrke G, Neufeld EB, Meads T, Shanks MR, Cassio D, Laurent M et al. WIF-B cells: an in vitro model for studies of hepatocyte polarity. J Cell Biol 1993; 123: 1761-1775.
14. Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system. Methods Enzymol 1998; 292: 456-473.
15. Isshiki K, Nakao A, Ito M, Hamaguchi M, Takagi H. P-glycoprotein expression in human primary liver cancer and cirrhosis. J Hepatol 1993; 18: 168-172.
16. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996; 56: 4332-4337.
17. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 1994; 70: 239-243.
18. Masuda Y, Kobayashi H, Holland JF, Ohnuma T. Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex. Cancer Chemother Pharmacol 1998; 42: 9-16.
19. Materna V, Liedert B, Thomale J, Lage H. Protection of platinum-DANN adduct formation and reversal of cisplatin resistance by anti-ABCC2 hammerhead ribozymes in human cancer cells. Int J Cancer 2005; 115: 393-402.
20. Itoh Y, Tamai M, Yokogawa K, Nomura M, Moritani S, Suzuki H et al. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 2002; 22: 1649-1653.
21. Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, ABCC2; and BCRP. Mol Ther 2005; 11: 508-522.
22. Lischka K, Starke D, Failing K, Herling A, Kramer W, Petzinger E. Hepatobiliary elimination of bile acid-modified oligodeoxynucleotides in Wistar and TR-rats: evidence for ABCC2 as carrier for oligodeoxynucleotides. Biochem Pharmacol 2003; 66: 565-577.
23. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55: 5283-5287.
24. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T et al. In vivo gene therapy for a-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461-465.
25. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
26. Li B, Gou XH, Chen L, Li DH, Zhao YH, Han L et al. Construction of the recombinant adenovirus vector carrying antisense multidrug resistance gene. Hepatobiliary Pancreat Dis Int 2006; 5: 80-84.
27. Cantz T, Nies AT, Brom M, Hofmann AF, Keppler D. ABCC2 a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. Am J Physiol Gastrointest Liver Physiol 2000; 278: G522-G531 80-84.